Brief: Revive Therapeutics engages Massachusetts General Hospital for cystinuria phase 2 study
12/01/2017 12:02
Jan 12 (Reuters) - Revive Therapeutics Ltd RVV.V
* Revive Therapeutics engages Massachusetts General Hospital
for cystinuria phase 2 study
Source text for Eikon: urn:newsml:reuters.com:*:nMKWH6j4za
Further company coverage: RVV.V
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure